Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism

FASEB Journal

Volumn 20, Issue 12, 2006, Pages 2009-2016

  Borthwick, Gillian M ^a   Johnson, A Sarah ^c   Partington, Matthew ^a   Burn, John ^a   Wilson, Robert ^b   Arthur, Helen M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c NONE

Author keywords

Cancer; Celecoxib; Endothelial cells; SC560

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; SALICYLIC ACID; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; ASPIRIN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SALICYLIC ACID; SULFONAMIDES;

EID: 33750097303     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-5987com     Document Type: Article

References (58)

1. Thun, M. J., Henley, S. J., and Patrono, C. (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94, 252-266
2. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y., et al. (2003) Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197, 221-232
3. Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. (2000) Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589-1594
4. Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., Lane, T. F., and Hla, T. (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101, 591-596
5. Wang, D., and DuBois, R. N. (2004) Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc. Natl. Acad. Sci. U. S. A. 101, 415-416
6. Shtivelband, M. I., Juneja, H. S., Lee, S., and Wu, K. K. (2003) Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J. Thromb. Haemost. 1, 2225-2233
7. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899
8. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890
9. Benamouzig, R., Deyra, J., Martin, A., Girard, B., Jullian, E., Piednoir, B., Couturier, D., Coste, T., Little, J., and Chaussade, S. (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125, 328-336
10. Hurwitz, H., and Kabbinavar, F. (2005) Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 69, Suppl. 3, 17-24
11. Vane, J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235
12. Funk, C. D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875
13. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. (1993) Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268, 9049-9054
14. Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., and Needleman, P. (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265, 16737-16740
15. Masferrer, J. L., Zweifel, B. S., Seibert, K., and Needleman, P. (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 86, 1375-1379
16. Botting, R., and Ayoub, S. S. (2005) COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot. Essent. Fatty Acids 72, 85-87
17. Lanas, A. (2001) Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications. Eur. J. Gastroenterol. Hepatol. 13, 623-626
18. Sheehan, K. M., O'Connell, F., O'Grady, A., Conroy, R. M., Leader, M. B., Byrne, M. F., Murray, F. E., and Kay, E. W. (2004) The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas. Eur. J. Gastroenterol. Hepatol. 16, 619-625
19. Williams, C. S., Shattuck-Brandt, R. L., and DuBois, R. N. (1999) The role of COX-2 in intestinal cancer. Expert Opin. Investig. Drugs 8, 1-12
20. Chapple, K. S., Scott, N., Guillou, P. J., Coletta, P. L., and Hull, M. A. (2002) Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J. Pathol. 198, 435-441
21. Masunaga, R., Kohno, H., Dhar, D. K., Ohno, S., Shibakita, M., Kinugasa, S., Yoshimura, H., Tachibana, M., Kubota, H., and Nagasue, N. (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res. 6, 4064-4068
22. Cianchi, F., Cortesini, C., Bechi, P., Fantappie, O., Messerini, L., Vannacci, A., Sardi, I., Baroni, G., Boddi, V., Mazzanti, R., et al. (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121, 1339-1347
23. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188
24. Mann, J. R., and DuBois, R. N. (2004) Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 10, 145-152
25. Koehne, C. H., and Dubois, R. N. (2004) COX-2 inhibition and colorectal cancer. Semin. Oncol. 31, 12-21
26. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952
27. Zhang, Y., Shaffer, A., Portanova, J., Seibert, K., and Isakson, P. C. (1997) Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther. 283, 1069-1075
28. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., and Bertagnolli, M. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080
29. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31
30. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., and Lawley, T. J. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99, 683-690
31. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
32. Yang, S., Graham, J., Kahn, J. W., Schwartz, E. A., and Gerritsen, M. E. (1999) Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am. J. Pathol. 155, 887-895
33. Chen, J. X., Chen, Y., DeBusk, L., Lin, W., and Lin, P. C. (2004) Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 287, H187-195
34. Premzl, A., Turk, V., and Kos, J. (2006) Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J. Cell. Biochem. 6, 1230-1240
35. Frantz, B., and O'Neill, E. A. (1995) The effect of sodium salicylate and aspirin on NF-kappa B. Science 270, 2017-2019
36. Baatout, S. (1997) Endothelial differentiation using Matrigel (review). Anticancer Res. 17, 451-455
37. Kahn, J., Mehraban, F., Ingle, G., Xin, X., Bryant, J. E., Vehar, G., Schoenfeld, J., Grimaldi, C. J., Peale, F., Draksharapu, A., et al. (2000) Gene expression profiling in an in vitro model of angiogenesis. Am. J. Pathol. 156, 1887-1900
38. Bell, S. E., Mavila, A., Salazar, R., Bayless, K. J., Kanagala, S., Maxwell, S. A., and Davis, G. E. (2001) Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 114, 2755-2773
39. Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., and Isakson, P. C. (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U. S. A. 95, 13313-13318
40. Schwenger, P., Bellosta, P., Vietor, I., Basilico, C., Skolnik, E. Y., and Vilcek, J. (1997) Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. U. S. A. 94, 2869-2873
41. Pillinger, M. H., Capodici, C., Rosenthal, P., Kheterpal, N., Hanft, S., Philips, M. R., and Weissmann, G. (1998) Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc. Natl. Acad. Sci. U. S. A. 95, 14540-14545
42. Kopp, E., and Ghosh, S. (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265, 956-959
43. Stark, L. A., Din, F. V., Zwacka, R. M., and Dunlop, M. G. (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 15, 1273-1275
44. Wallace, J. L. (1997) Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112, 1000-1016
45. Buchanan, F. G., Chang, W., Sheng, H., Shao, J., Morrow, J. D., and DuBois, R. N. (2004) Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology 127, 1391-1400
46. Yoshida, S., Amano, H., Hayashi, I., Kitasato, H., Kamata, M., Inukai, M., Yoshimura, H., and Majima, M. (2003) COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab. Invest. 83, 1385-1394
47. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306-1311
48. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716
49. Gately, S., and Li, W. W. (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 31, 2-11
50. Leahy, K. M., Ornberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62, 625-631
51. Gerber, H. P., Dixit, V., and Ferrara, N. (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273, 13313-13316
52. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343
53. Abdelrahim, M., and Safe, S. (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of sp1 and sp4 proteins. Mol. Pharmacol. 68, 317-329
54. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tarnawski, A. S. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5, 1418-1423
55. Charo, I. F., Shak, S., Karasek, M. A., Davison, P. M., and Goldstein, I. M. (1984) Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J. Clin. Invest. 74, 914-919
56. Laneuville, O., Breuer, D. K., Dewitt, D. L., Hla, T., Funk, C. D., and Smith, W. L. (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271, 927-934
57. Tegeder, I., Pfeilschifter, J., and Geisslinger, G. (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15, 2057-2072
58. Meadows, K. N., Bryant, P., Vincent, P. A., and Pumiglia, K. M. (2004) Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23, 192-200